The FDAs approval of resmetirom changes the MASH drug development landscape for the better after years of failed programs 3
One MCL addresses gastrointestinal injuries, while the other handles Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) vision loss claims, sometimes called an eye stroke
The intervention led to significant effects as shown by the significant treatment visit interactions observed in all the glycemia related biomarkers and the significant differences between groups in the rate of change of FBG and HbA1c (Table 2), which showed opposite directions during the intervention, decreasing in MO and increasing in PLC
All that remains to be seen, and an absolute benefit of 1.5 per 100 people treated is certainly nothing to write home about
The lowest dose is expected to cost about $149 a month for people paying out of pocket, in line with the Wegovy pill
Finding other things to occupy your mind can also reduce food noise